Home  >  News
Corporate + Font Resize -

Glenmark receives US FDA tentative approval for generic Gilenya capsules

Our Bureau, Mumbai
Monday, March 20, 2017, 14:30 Hrs  [IST]

The United States Food & Drug Administration (FDA) has granted tentative approval for Glenmark Pharmaceuticals' fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Novartis Pharmaceuticals. According to IMS Health sales data for the 12 month period ending January 2017, Gilenya capsules, 0.5 mg achieved annual sales of approximately $2.03 billion.

Glenmark’s current portfolio consists of 112 products authorized for distribution in the US marketplace and approximately 65 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. All brand names and trademarks are the property of their respective owners. 1Market includes brand and all available therapeutic equivalents IMS Health National Sales Perspectives: Retail & Non-Retail, January 2017

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. It is ranked among the top 80 pharma and biotec companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2016).

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
VIJAY Apr 17, 2017 9:07 AM
Hi

Pl provide your updates
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |